CCS
PFE icon

Concentric Capital Strategies’s Pfizer PFE Stock Holding History

Concentric Capital Strategies’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-387,698
Closed -$9.88M – 358
2025
Q3 		$9.88M Buy
+387,698
New +$9.57M 0.44% 63
2022
Q2 		– Sell
-38,300
Closed -$1.98M – 154
2022
Q1 		$1.98M Buy
+38,300
New +$1.99M 0.65% 67

Other funds holding PFE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
State Farm Mutual Automobile Insurance
State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Concentric Capital Strategies's PFE Position: Q4 2025 in Review

Concentric Capital Strategies sold out of Pfizer (PFE) in Q4 2025, closing a stake of 387,698 shares — an estimated $9.88M sold.

Concentric Capital Strategies first reported a position in PFE in Q1 2022 and held it in 2 quarters. The position peaked at $9.88M in Q3 2025. 2,906 funds tracked by Wall St. Rank hold PFE as of Q4 2025.

  • Concentric Capital Strategies reported no remaining Pfizer position as of Q4 2025 after selling out during the quarter.
  • Concentric Capital Strategies sold 387,698 Pfizer shares in Q4 2025, an estimated $9.88M.
  • Concentric Capital Strategies first reported a position in Pfizer in Q1 2022 and held it in 2 quarters.
  • Concentric Capital Strategies's Pfizer position peaked at $9.88M in Q3 2025.
  • 2,906 funds tracked by Wall St. Rank held Pfizer as of Q4 2025.

Based on Concentric Capital Strategies's 13F filing for Q4 2025, filed 17 Feb 2026.